Literature DB >> 10024047

Genetic analysis of human immunodeficiency virus in Abidjan, Ivory Coast reveals predominance of HIV type 1 subtype A and introduction of subtype G.

D L Ellenberger1, D Pieniazek, J Nkengasong, C C Luo, S Devare, C Maurice, M Janini, A Ramos, C Fridlund, D J Hu, I M Coulibaly, E Ekpini, S Z Wiktor, A E Greenberg, G Schochetman, M A Rayfield.   

Abstract

To better understand the molecular epidemiology of HIV genetic diversity in Abidjan, Ivory Coast, we performed a genetic analysis of 170 HIV-1-seropositive specimens representing newly diagnosed tuberculosis patients (n = 143) and women monitored in a mother-to-child transmission cohort study (n = 27). Preliminary screening with RFLP presumptively classified 162 (95.3%) of these as subtype A. The envelope region of 108 specimens was subtyped by sequence analysis: 102 (94.4%) were subtype A, 2 (1.9%) were subtype D, and 4 (3.7%) were subtype G. Subtyping gag and env regions of the genome suggested that five of the six nonsubtype A isolates exhibited a potentially mosaic structure. A comparative phylogenetic analysis of HIV-1 subtype A C2V3 from 27 Ivory Coast and 21 Ugandan sequences revealed a striking clustering among Ivory Coast variants, and an independent segregation from Ugandan subtype A. Despite independent clustering with other subtype A specimens, limited variability of the V3 loop apex was observed; the globally predominant V3 motif, GPGQ, represented 90.1% of the HIV-1 strains. This study demonstrates that clade A is the predominant HIV-1 subtype in HIV-seropositive individuals in Abidjan, Ivory Coast and that these strains are phylogenetically distinct from other subtype A strains observed in East Africa.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10024047     DOI: 10.1089/088922299311655

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  11 in total

1.  Development and evaluation of a DNA enzyme immunoassay method for env genotyping of subtypes A through G of human immunodeficiency virus type 1 group M, with discrimination of the circulating recombinant forms CRF01_AE and CRF02_AG.

Authors:  Jean-Christophe Plantier; Laurence Vergne; Florence Damond; Souleymane MBoup; Eitel MPoudi-NGole; Laurence Buzelay; Isabelle Farfara; Denys Brand; Martine Peeters; Françoise Brun-Vézinet; Eric Delaporte; Francis Barin
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

2.  Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy.

Authors:  B Chaplin; G Eisen; J Idoko; D Onwujekwe; E Idigbe; I Adewole; W Gashau; S Meloni; A D Sarr; J L Sankalé; E Ekong; R L Murphy; P Kanki
Journal:  AIDS Res Hum Retroviruses       Date:  2010-10-21       Impact factor: 2.205

3.  Simplified strategy for detection of recombinant human immunodeficiency virus type 1 group M isolates by gag/env heteroduplex mobility assay. Study Group on Heterogeneity of HIV Epidemics in African Cities.

Authors:  L Heyndrickx; W Janssens; L Zekeng; R Musonda; S Anagonou; G Van der Auwera; S Coppens; K Vereecken; K De Witte; R Van Rampelbergh; M Kahindo; L Morison; F E McCutchan; J K Carr; J Albert; M Essex; J Goudsmit; B Asjö; M Salminen; A Buvé; G van Der Groen
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  Viral Genetic Diversity and Polymorphisms in a Cohort of HIV-1-Infected Patients Eligible for Initiation of Antiretroviral Therapy in Abuja, Nigeria.

Authors:  Karidia Diallo; Du-Ping Zheng; Erin K Rottinghaus; Orji Bassey; Chunfu Yang
Journal:  AIDS Res Hum Retroviruses       Date:  2015-02-05       Impact factor: 2.205

5.  Human immunodeficiency virus type 1 group m protease in cameroon: genetic diversity and protease inhibitor mutational features.

Authors:  Peter N Fonjungo; Eitel N Mpoudi; Judith N Torimiro; George A Alemnji; Laura T Eno; Esther J Lyonga; John N Nkengasong; Renu B Lal; Mark Rayfield; Marcia L Kalish; Thomas M Folks; Danuta Pieniazek
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

6.  Molecular epidemiology of human immunodeficiency virus type 1 sub-subtype A3 in Senegal from 1988 to 2001.

Authors:  Seema Thakore Meloni; Jean-Louis Sankalé; Donald J Hamel; Geoffrey Eisen; Aissatou Guéye-Ndiaye; Souleymane Mboup; Phyllis J Kanki
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

7.  Comparison of NucliSens and Amplicor monitor assays for quantification of human immunodeficiency virus type 1 (HIV-1) RNA in plasma of persons with HIV-1 subtype A infection in Abidjan, Côte d'Ivoire.

Authors:  J N Nkengasong; M Kalou; C Maurice; C Bile; M Y Borget; S Koblavi; E Boateng; M Sassan-Morokro; E Anatole-Ehounou; P Ghys; A E Greenberg; S Z Wiktor
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

8.  The predominance of Human Immunodeficiency Virus type 1 (HIV-1) circulating recombinant form 02 (CRF02_AG) in West Central Africa may be related to its replicative fitness.

Authors:  Harr F Njai; Youssef Gali; Guido Vanham; Claude Clybergh; Wim Jennes; Nicole Vidal; Christelle Butel; Eitel Mpoudi-Ngolle; Martine Peeters; Kevin K Ariën
Journal:  Retrovirology       Date:  2006-07-03       Impact factor: 4.602

9.  Recombinant viruses and early global HIV-1 epidemic.

Authors:  Marcia L Kalish; Kenneth E Robbins; Danuta Pieniazek; Amanda Schaefer; Nzila Nzilambi; Thomas C Quinn; Michael E St Louis; Ae S Youngpairoj; Jonathan Phillips; Harold W Jaffe; Thomas M Folks
Journal:  Emerg Infect Dis       Date:  2004-07       Impact factor: 6.883

10.  Mortality associated with HIV-1, HIV-2, and HTLV-I single and dual infections in a middle-aged and older population in Guinea-Bissau.

Authors:  Birgitta Holmgren; Zacarias da Silva; Pernille Vastrup; Olav Larsen; Sören Andersson; Henrik Ravn; Peter Aaby
Journal:  Retrovirology       Date:  2007-11-27       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.